Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel and gemcitabine for locally advanced unresectable pancreatic cancer
ChiCTR2300077532Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Objective response rate and Progression-free survival. Started Nov 2023; status: recruiting.
02
Drugs
camrelizumabpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2300077532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077532.